Company Description
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.
It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder.
The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
| Country | Ireland |
| Founded | 2003 |
| IPO Date | Jun 1, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,800 |
| CEO | Bruce Cozadd |
Contact Details
Address: Waterloo Exchange, Fifth Floor Dublin, D04 E5W7 Ireland | |
| Phone | 353 1 634 7800 |
| Website | jazzpharma.com |
Stock Details
| Ticker Symbol | JAZZ |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001232524 |
| CUSIP Number | G50871105 |
| ISIN Number | IE00B4Q5ZN47 |
| Employer ID | 98-1032470 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bruce C. Cozadd | Co-Founder, Chairman and Chief Executive Officer |
| Renee D. Gala | President and Chief Operating Officer |
| Philip L. Johnson | Executive Vice President and Chief Financial Officer |
| Patricia Carr | Senior Vice President and Chief Accounting Officer |
| Dr. Robert Iannone M.D. | Executive Vice President, Chief Medical Officer and Global Head of Research and Development |
| Samantha Pearce | Executive Vice President and Chief Commercial Officer |
| Jeff Macdonald | Executive Director of Investor Relations |
| Neena M. Patil J.D. | Executive Vice President and Chief Legal Officer |
| Heidi Manna | Executive Vice President and Chief People Officer |
| Dr. Jed Black M.D. | Senior Vice President of Sleep and CNS Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 25, 2025 | 8-K | Current Report |
| Jul 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 10, 2025 | 8-K | Current Report |
| Jul 1, 2025 | 144 | Filing |
| Jun 6, 2025 | ARS | Filing |
| Jun 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 6, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 2, 2025 | 144 | Filing |
| May 23, 2025 | PRE 14A | Other preliminary proxy statements |